Covance Acquires Medaxial
Expanding global market access, reimbursement, and communications solutions.
Covance (NYSE: CVD), one of the world’s largest and most comprehensive drug development services companies, today announced it has acquired Medaxial, a London-based value communication consultancy. The company specializes in offering clients an integrated approach to market access strategy, health economic modeling, and data dissemination services, and focuses on defining and communicating the value of a biopharmaceutical product or medical device to healthcare payers and the stakeholders who influence them.
“Covance is a leader in the rapidly growing sector of market access and reimbursement. Medaxial, with their proven expertise in optimizing data-driven, solution-focused communication of a medical product’s value will further complement our market access offerings,” said Marc Ginsky, Vice President and General Manager, Covance Market Access. “Proactive and effective communication of clinical and economic value is critical to help clients navigate an increasingly complex drug development and payment landscape, as they strive to provide innovative medical products to patients.”
With the acquisition of Medaxial, Covance’s market access services, which currently has offices in Gaithersburg, Md., Greenfield, Ind., San Diego and Sydney, will be better positioned to serve clients worldwide. In addition to Medaxial’s corporate headquarters in London, the company has employees in New York and Antwerp, Belgium.
“Our capabilities and our commitment to client service are in line with Covance’s commitment to operational and service excellence,” said Paul Mcloughlin, co-founder and Director, Technology and Design, Medaxial. “This acquisition will provide clients with the benefits of a global consultancy group with local expertise.” Mcloughlin, along with John Fanshawe, co-founder and Managing Director at Medaxial, will continue working with the company after the acquisition is completed.
“This acquisition will enhance Covance’s ability to bring value communication solutions to our clients, beginning early in drug development and continuing through regulatory approval, reimbursement, and commercial success,” said Ginsky.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
